Welcome to the Retatrutide Australia blog. This is where we'll publish ongoing coverage of Eli Lilly's triple hormone receptor agonist as it moves through Phase 3 trials towards regulatory approval.

What to expect here

  • Clinical trial updates — results and milestones from the TRIUMPH Phase 3 program
  • Australian regulatory news — TGA submission and approval progress
  • Access information — how and where Australians will be able to access Retatrutide once approved
  • Comparisons and explainers — how Retatrutide stacks up against Ozempic, Wegovy and Mounjaro

Stay in the loop

If you'd rather get updates delivered to your inbox, join the notification list on our homepage and we'll email you when there's meaningful news.

This site is independent and not affiliated with Eli Lilly. Content is informational only and not medical advice.